Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer

Our understanding of breast cancer heterogeneity at the protein level is limited despite proteins being the ultimate effectors of cellular functions. We investigated the heterogeneity of breast cancer (41 primary tumors and 15 breast cancer cell lines) at the protein and phosphoprotein levels to identify activated oncogenic pathways and developing targeted therapeutic strategies. Heterogeneity was observed not only across histological subtypes, but also within subtypes. Tumors of the Triple negative breast cancer (TNBC) subtype distributed across four different clusters where one cluster (cluster ii) showed high deregulation of many proteins and phosphoproteins. The majority of TNBC cell lines, particularly mesenchymal lines, resembled the cluster ii TNBC tumors. Indeed, TNBC cell lines were more sensitive than non-TNBC cell lines when treated with targeted inhibitors selected based on upregulated pathways in cluster ii. In line with the enrichment of the upregulated pathways with onco-clients of Hsp90, we found synergy in combining Hsp90 inhibitors with several kinase inhibitors, particularly Erk5 inhibitors. The combination of Erk5 and Hsp90 inhibitors was effective in vitro and in vivo against TNBC leading to upregulation of pro-apoptotic effectors. Our studies contribute to proteomic profiling and improve our understanding of TNBC heterogeneity to provide therapeutic opportunities for this disease.

[1]  G. Mills,et al.  Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Yan Tang,et al.  MEK5/ERK5 Signaling Suppresses Estrogen Receptor Expression and Promotes Hormone-Independent Tumorigenesis , 2013, PloS one.

[3]  Shantanu Banerji,et al.  Molecular Pathways Molecular Pathways : PI 3 K Pathway Targets in Triple-Negative Breast Cancers , 2013 .

[4]  G. Mills,et al.  Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  N. Gómez,et al.  Canonical and Kinase Activity-Independent Mechanisms for Extracellular Signal-Regulated Kinase 5 (ERK5) Nuclear Translocation Require Dissociation of Hsp90 from the ERK5-Cdc37 Complex , 2013, Molecular and Cellular Biology.

[6]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[7]  H. Brinkhaus,et al.  JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. , 2012, Cancer cell.

[8]  K. Finegan,et al.  The extracellular-regulated protein kinase 5 (ERK5) promotes cell proliferation through the down-regulation of inhibitors of cyclin dependent protein kinases (CDKs). , 2012, Cellular signalling.

[9]  I. Gromova,et al.  Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer* , 2012, Molecular & Cellular Proteomics.

[10]  M. Krzywinski,et al.  MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition , 2012, Oncogene.

[11]  J. Lim,et al.  Laminar Flow Activation of ERK5 Protein in Vascular Endothelium Leads to Atheroprotective Effect via NF-E2-related Factor 2 (Nrf2) Activation* , 2012, The Journal of Biological Chemistry.

[12]  S. Pelech,et al.  Using protein microarrays to study phosphorylation-mediated signal transduction. , 2012, Seminars in cell & developmental biology.

[13]  Susan Lindquist,et al.  Quantitative Analysis of Hsp90-Client Interactions Reveals Principles of Substrate Recognition , 2012, Cell.

[14]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[15]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[16]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[17]  Bernhard Kuster,et al.  Systematic Identification of the HSP90 Regulated Proteome , 2012, Molecular & Cellular Proteomics.

[18]  M. Burow,et al.  MEK5/ERK5 pathway: the first fifteen years. , 2012, Biochimica et biophysica acta.

[19]  S. Larson,et al.  Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. , 2011, Nature chemical biology.

[20]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[21]  K. Coombes,et al.  Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer , 2011, Clinical Proteomics.

[22]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[23]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[24]  C. Lange,et al.  Met Receptors Induce Sam68-dependent Cell Migration by Activation of Alternate Extracellular Signal-regulated Kinase Family Members* , 2011, The Journal of Biological Chemistry.

[25]  Jiing-Dwan Lee,et al.  Targeting the BMK1 MAP Kinase Pathway in Cancer Therapy , 2011, Clinical Cancer Research.

[26]  T. Conrads,et al.  Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues. , 2011, Journal of proteome research.

[27]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[28]  David R. Croucher,et al.  Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. , 2010, Cancer research.

[29]  K. Coombes,et al.  A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers , 2010, Clinical Proteomics.

[30]  C. Lange,et al.  Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells , 2010, Breast Cancer Research.

[31]  Vilppu J Tuominen,et al.  ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 , 2010, Breast Cancer Research.

[32]  Stephen Fox,et al.  HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer , 2010, Breast Cancer Research.

[33]  J. Lee,et al.  Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival , 2010, BMC Cancer.

[34]  A. Melnick,et al.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models , 2009, Proceedings of the National Academy of Sciences.

[35]  J. Montero,et al.  Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target , 2009, PloS one.

[36]  M. Brattain,et al.  A novel role of ERK5 in integrin‐mediated cell adhesion and motility in cancer cells via Fak signaling , 2009, Journal of cellular physiology.

[37]  Yan Tang,et al.  Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype , 2008, Breast Cancer Research.

[38]  Mariaelena Pierobon,et al.  Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. , 2008, Journal of proteome research.

[39]  Yingdong Zhao,et al.  BRB-ArrayTools Data Archive for Human Cancer Gene Expression: A Unique and Efficient Data Sharing Resource , 2008, Cancer informatics.

[40]  Tony J Collins,et al.  ImageJ for microscopy. , 2007, BioTechniques.

[41]  Andreas Beyer,et al.  Posttranscriptional Expression Regulation: What Determines Translation Rates? , 2007, PLoS Comput. Biol..

[42]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[43]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[44]  V. Thorsson,et al.  Integrated Genomic and Proteomic Analyses of Gene Expression in Mammalian Cells*S , 2004, Molecular & Cellular Proteomics.

[45]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[46]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[47]  R. Hipskind,et al.  Activation of cyclin D1 expression by the ERK5 cascade , 2003, Oncogene.

[48]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[49]  C. Li,et al.  Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.